Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Conditions: Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis

Sex: All

Ages: 65 Years – N/A

Healthy volunteers: No

Phase: NA

Enrollment: 515

Sponsor: Massachusetts General Hospital

Summary

Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.

Eligibility Criteria

Inclusion Criteria: * Patients with a confirmed diagnosis of HFpEF. * Age ≥65 years old Exclusion Criteria: * End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05577819). StuddyBuddy aggregates publicly available trial information.